DK2498796T3 - Behandling af hjertesygdom - Google Patents

Behandling af hjertesygdom Download PDF

Info

Publication number
DK2498796T3
DK2498796T3 DK10829273.1T DK10829273T DK2498796T3 DK 2498796 T3 DK2498796 T3 DK 2498796T3 DK 10829273 T DK10829273 T DK 10829273T DK 2498796 T3 DK2498796 T3 DK 2498796T3
Authority
DK
Denmark
Prior art keywords
igf
stem cells
cardiac stem
cardiac
hcscs
Prior art date
Application number
DK10829273.1T
Other languages
English (en)
Inventor
Jan Kajstura
Piero Anversa
Annarosa Leri
Original Assignee
Aal Scient Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aal Scient Inc filed Critical Aal Scient Inc
Application granted granted Critical
Publication of DK2498796T3 publication Critical patent/DK2498796T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (14)

1. Sammensætning af hjertestamceller, der udtrykker IGF-1-receptor, men ingen IGF-2 receptor, og som omfatter en effektiv mængde af IGF-2.
2. Sammensætning ifølge krav 1, der endvidere indbefatter en effektiv mængde af IGF-1.
3. Sammensætning ifølge krav 1 eller krav 2, der endvidere omfatter en farmaceutisk acceptabel bærer.
4. Sammensætning ifølge krav 1 eller krav 2, der endvidere omfatter et cellekulturmedium.
5. Sammensætning ifølge et hvilket som helst af kravene 2-4, hvor den effektive mængde af IGF-1 er tilstrækkelig til at øge proliferation af hjertestamcelleme med mindst ca. 10 %, sammenlignet med hjertestamceller i fravær af IGF-1, eller hvor den effektive mængde afIGF-1 er ca. 100ng/mF.
6. Sammensætning ifølge et hvilket som helst af kravene 1-5, hvor den effektive mængde af IGF-2 er tilstrækkelig til at øge ekspression af mindst én markør for myocytdifferentiering med mindst ca. 10 %, sammenlignet med hjertestamceller i fravær af IGF-2, eller hvor den effektive mængde af IGF-2 er ca. 100 ng/mF.
7. Sammensætning ifølge krav 6, hvor markøren for myocytdifferentiering er udvalgt fra gruppen bestående af: α-sarkomer aktin, connexin-43, Nkx2.5, GATA-4 og MEF2C.
8. Sammensætning ifølge et hvilket som helst af kravene 2-7, hvor IGF-2 er tilsat, efter at hjertestamcelleme er bragt i kontakt med IGF-1.
9. Sammensætning ifølge krav 8, hvor hjertestamcelleme er bragt i kontakt med IGF-1 i mindst ca. 12 timer.
10. Sammensætning ifølge et hvilket som helst af kravene 1-9, hvor hjertestamcelleme er isoleret fra en persons myokardievæv.
11. Sammensætning ifølge krav 1 eller 2 til anvendelse i behandlingen af en person, der er diagnosticeret med eller lider af kardiovaskulær sygdom.
12. Sammensætning ifølge krav 1 eller 2 til anvendelsen ifølge krav 11, hvor personen har et beskadiget myokardium; og/eller er diagnosticeret med eller lider af et myokardieinfarkt; og/eller er diagnosticeret med eller lider af en hjerteinsufficiens; og/eller er diagnosticeret med eller lider af en aldersrelateret kardiomyopati.
13. Sammensætning ifølge krav 1 eller 2 til anvendelsen ifølge et hvilket som helst af kravene 11-12, hvor sammensætningen administreres til et område af et beskadiget hjertevæv, eventuelt ved injektion, eller eventuelt ved hjælp af et kateter; og hvor administrationen eventuelt er intrakoronær administration.
14. Sammensætning ifølge krav 1 eller 2 til anvendelsen ifølge et hvilket som helst af kravene 11-13, hvor de hjertestamceller, der skal administreres til personen, bringes i kontakt med IGF-2, i et tidsrum, der er tilstrækkeligt til at øge myocytdannelse, sammenlignet med hjertestamceller i fravær af IGF-2; og/eller hvor hjertestamcelleme bringes i kontakt med IGF-2 i et tidsrum, der er tilstrækkeligt for hjertestamcelleme til at overføre tilegnelse af mindst én adult kardiomyocyt-fænotype, sammenlignet med hjertestamceller i fravær af IGF-2; og hvor den adulte kardiomyocyt-fænotype eventuelt er udvalgt fra gruppen bestående af: et myocytvolumen større end 2000 μητ\ kontraktilitet som reaktion på elektrisk stimulation, en forlænget morfologi, calciumtolerance, ekspression af mindst ét kontraktilt protein og aktivering af j emstrømskanaler; og hvor det kontraktile protein eventuelt er udvalgt fra gruppen bestående af: a-sarkomer aktin, tunge myosinkæder, lette myosinkæder og tropomyosin; og/eller hvor hjertestamcelleme bringes i kontakt med IGF-2 i ca. 2 timer.
DK10829273.1T 2009-11-09 2010-11-09 Behandling af hjertesygdom DK2498796T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25935109P 2009-11-09 2009-11-09
PCT/US2010/055993 WO2011057249A2 (en) 2009-11-09 2010-11-09 Treatment of heart disease

Publications (1)

Publication Number Publication Date
DK2498796T3 true DK2498796T3 (da) 2018-03-05

Family

ID=43970833

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10829273.1T DK2498796T3 (da) 2009-11-09 2010-11-09 Behandling af hjertesygdom

Country Status (4)

Country Link
US (3) US20120321595A1 (da)
EP (1) EP2498796B1 (da)
DK (1) DK2498796T3 (da)
WO (1) WO2011057249A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
WO2011057249A2 (en) 2009-11-09 2011-05-12 The Brigham And Women's Hospital, Inc. Treatment of heart disease
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
CA2881394C (en) 2012-08-13 2024-05-14 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
WO2014138682A1 (en) 2013-03-08 2014-09-12 University Of Vermont And State Agriculture College Compositions and methods for cardiac tissue repair
CA2929172A1 (en) 2013-10-30 2015-05-07 Jason MIKLAS Devices and methods for three-dimensional tissue culturing using contractile force
WO2015081094A1 (en) 2013-11-27 2015-06-04 University Of Louisville Research Foundation, Inc. Cardiac progenitor cells and methods of use therefor
US20150272999A1 (en) * 2014-03-31 2015-10-01 Banner Health Retrograde coronary vein delivery of stem cells
AU2015327812B2 (en) 2014-10-03 2021-04-15 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
US11253551B2 (en) 2016-01-11 2022-02-22 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
WO2018057542A1 (en) 2016-09-20 2018-03-29 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
JP7336769B2 (ja) 2017-04-19 2023-09-01 シーダーズ―シナイ メディカル センター 骨格筋ジストロフィーを治療する方法及び組成物
IT201700062176A1 (it) * 2017-06-07 2018-12-07 Univ Degli Studi Milano Metodo per l’isolamento di sottopopolazioni di progenitori cellulari cardiaci e relativi usi in campo medico
WO2019126068A1 (en) 2017-12-20 2019-06-27 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
CA3106078A1 (en) * 2018-07-17 2020-01-23 Junghun Lee Treatment of neuropathy with dna constructs expressing igf-1 isoforms

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3951140A (en) 1974-11-13 1976-04-20 Indianapolis Center For Advanced Research Ultrasonic therapy apparatus and method
US4867963A (en) 1987-01-29 1989-09-19 Temple University Of The Commonwealth System Of Higher Education Enhancement of NMR imaging of tissue by paramagnetic pyrophosphate contrast agent
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
US6205349B1 (en) 1998-09-29 2001-03-20 Siemens Medical Systems, Inc. Differentiating normal living myocardial tissue, injured living myocardial tissue, and infarcted myocardial tissue in vivo using magnetic resonance imaging
AU766077C (en) 1998-11-20 2004-10-07 Genentech Inc. Uses for Eph receptor antagonists and agonists to treat vascular disorders
US6242666B1 (en) 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US20110091428A1 (en) 2000-07-31 2011-04-21 New York Medical College Compositions of adult organ stem cells and uses thereof
US7547674B2 (en) 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2002089657A2 (en) 2001-05-04 2002-11-14 Biosite, Inc. Diagnostic markers of acute coronary syndromes and methods of use thereof
WO2003033697A1 (en) 2001-10-18 2003-04-24 Ixion Biotechnology, Inc. Conversion of liver stem and progenitor cells to pancreatic functional cells
US20050152899A1 (en) 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
MXPA03004105A (es) 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
US20040158289A1 (en) 2002-11-30 2004-08-12 Girouard Steven D. Method and apparatus for cell and electrical therapy of living tissue
EP2266628A3 (en) 2003-05-13 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Method of determining the susceptibility to bone meatastases by EPhA2 expression
US20080292677A1 (en) 2004-12-09 2008-11-27 The Board Of Regents Of The University Of Texas System Engineered lung tissue, hydrogel/somatic lung progenitor cell constructs to support tissue growth, and method for making and using same
EP1516924A1 (en) * 2003-09-17 2005-03-23 Fundacion IVI para el Estudio de la reproduccion Humana (FIVIER) Generation of human embryonic stem cells from triploid zygotes
US20050187607A1 (en) 2004-02-20 2005-08-25 Akhtar Adil J. Drug delivery device
JP2008518022A (ja) 2004-10-27 2008-05-29 メディミューン，インコーポレーテッド 線維症関連疾患を治療するためのＥｐｈＡ２およびエフリンＡ１モジュレーター
JP5202953B2 (ja) 2004-11-08 2013-06-05 ザ ジョンズ ホプキンス ユニバーシティー 心臓幹細胞
US8168588B2 (en) 2005-01-25 2012-05-01 Five Prime Therapeutics, Inc. Compositions comprising FGF-9 and betacellulin and methods for treating cardiac conditions
MX2007009403A (es) 2005-02-04 2007-10-02 Raven Biotechnologies Inc Anticuerpos que se unen a epha2 y metodos para usar los mismos.
GB0509305D0 (en) 2005-05-06 2005-06-15 Randox Lab Ltd Method
IL296832A (en) * 2005-10-18 2022-11-01 Nat Jewish Health A process for making red blood cells using immortal hematopoietic stem cells and erythropoietin
RU2008129827A (ru) 2005-12-21 2010-01-27 МЕДИММЬЮН, ЭлЭлСи (US) МОЛЕКУЛЫ EphA2-BiTE И ИХ ПРИМЕНЕНИЕ
US7875451B2 (en) * 2006-01-19 2011-01-25 The University Of Washington Formulation to improve survival of transplanted cells
US20090274665A1 (en) 2006-04-27 2009-11-05 Cell Therapy Technologies, Inc. Stem Cells For Treating Lung Diseases
UA97953C2 (uk) * 2006-06-09 2012-04-10 Новартіс Аг Стабілізовані поліпептиди інсуліноподібного фактора росту
WO2007149447A2 (en) 2006-06-16 2007-12-27 The Board Of Trustees Of The Leland Stanford Junior University Lung progenitor cells, assays, and uses thereof
EP2044122B1 (en) 2006-07-18 2018-03-28 Sanofi Antagonist antibody against epha2 for the treatment of cancer
US9765298B2 (en) * 2006-07-24 2017-09-19 Mayo Foundation For Medical Education And Research Methods and materials for providing cardiac cells
US20100093626A1 (en) 2006-12-15 2010-04-15 Bingcheng Wang Peptide and small molecule agonists of epha and their uses in disease
DE102006060835A1 (de) 2006-12-22 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung des akuten Koronarsyndroms mittels CT-proET-1 in Kombination mit NT-proBNP
KR20090019078A (ko) * 2007-08-20 2009-02-25 한훈 제대혈 다분화능 줄기세포 유래의 세포활성화물질을포함하는 조성물 및 이의 제조방법
EP2219656A2 (en) * 2007-11-09 2010-08-25 New York Medical College Methods for the repair and/or regeneration of damaged myocardium using variants of hepatocyte growth factor
EP2245140A2 (en) 2007-11-30 2010-11-03 New York Medical College Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure
US20090180998A1 (en) 2007-11-30 2009-07-16 Piero Anversa Methods of isolating non-senescent cardiac stem cells and uses thereof
CA2743698A1 (en) 2007-11-30 2009-06-11 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
KR20090080843A (ko) 2008-01-22 2009-07-27 영남대학교 산학협력단 급성 심근경색 진단킷트
EP2356227B1 (en) 2008-11-14 2018-03-28 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
US9446076B2 (en) * 2009-05-20 2016-09-20 Cardio3 Biosciences S.A. Pharmaceutical composition for the treatment of heart diseases
WO2011057249A2 (en) 2009-11-09 2011-05-12 The Brigham And Women's Hospital, Inc. Treatment of heart disease
US20120288481A1 (en) 2009-11-09 2012-11-15 The Brigham And Women's Hospital, Inc. Treatment of heart disease
EP2624847B1 (en) 2010-10-05 2017-09-13 AAL Scientifics, Inc. Human lung stem cells and uses thereof
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof

Also Published As

Publication number Publication date
US10568912B2 (en) 2020-02-25
US20160220614A1 (en) 2016-08-04
EP2498796A2 (en) 2012-09-19
EP2498796B1 (en) 2017-12-27
WO2011057249A2 (en) 2011-05-12
US9808489B2 (en) 2017-11-07
WO2011057249A3 (en) 2011-10-13
US20120321595A1 (en) 2012-12-20
EP2498796A4 (en) 2013-10-30
US20180055889A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
US10568912B2 (en) Treatment of heart disease
US20120288481A1 (en) Treatment of heart disease
Sanganalmath et al. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions
JP5292106B2 (ja) 損傷心筋の修復および／または再生の方法および組成物
Maltais et al. The paracrine effect: pivotal mechanism in cell-based cardiac repair
JP6061345B2 (ja) 心臓修復のための骨髄由来ｃｄ２７１前駆細胞
US20110091428A1 (en) Compositions of adult organ stem cells and uses thereof
WO2009073616A2 (en) Compositions comprising vascular and myocyte progenitor cells and methods of their use
Soejitno et al. Clinical applications of stem cell therapy for regenerating the heart
Schoenhard et al. Stem cell therapy: pieces of the puzzle
Nigro et al. c-kit+ cells: the tell-tale heart of cardiac regeneration?
Formigli et al. Skeletal myoblasts for heart regeneration and repair: state of the art and perspectives on the mechanisms for functional cardiac benefits
JP2022503847A (ja) 治療適用のための骨髄由来ニューロキニン－１受容体陽性（ｎｋ１ｒ＋）前駆細胞
Pelacho et al. Stem cells and cardiac disease: where are we going?
Winter From cardiogenesis to cardiac regeneration: focus on epicardium-deri ed cells
Tchao Engineered human cardiac tissue from muscle derived stem cells
FANTON Myocardial Regenerative Capacities of the Cardiac Atrial Appendage Stem Cell
Sherin Age-dependent variation in stem cell characteristics of the healthy and diseased heart
van Laake et al. Human cardiomyocyte progenitor cells regenerate infarcted myocardium and preserve long-term cardiac function in mice
Class et al. Patent application title: METHODS AND COMPOSITIONS FOR THE REPAIR AND/OR REGENERATION OF DAMAGED MYOCARDIUM Inventors: Piero Anversa (Boston, MA, US)
Zembala et al. Tissue Engineering of the Heart
Xiang Improving Cardiac Repair by Stem Cell Factor Post-Myocardial Infarction
Noiseux et al. STEM CELLS THERAPY FOR ISCHEMIC CARDIOVASCULAR DISEASES: NEW INSIGHTS ON MECHANISMS AND FATE OF THE IMPLANTED CELLS